PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis.

Next Previous
Trial Profile

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2012

At a glance

  • Drugs Aspirin/dipyridamole (Primary) ; Telmisartan (Primary) ; Aspirin; Clopidogrel
  • Indications Embolism and thrombosis; Stroke
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PRoFESS
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 26 Jun 2012 Magnetic resonance imaging substudy results published in Stroke.
    • 30 Aug 2010 A late-breaking analysis reviewing 21 trials, including PROFESS, was presented at the European Society of Cardiology (ESC) Congress, according to a European Society of Cardiology media release.
    • 23 Jun 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top